Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03863080 · ClinicalTrials.gov registry record · Phase 2
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
A Phase 2 study of Myasthenia Gravis, sponsored by Immunovant Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
- 20
- Study locations
NCT03863080: Completed Phase 2 study of Myasthenia Gravis, sponsored by Immunovant Sciences.
NCT03863080 is a Phase 2 study of Myasthenia Gravis that has completed, run by Immunovant Sciences. The registered enrollment target is 17 participants, below the 191-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03863080, a Phase 2 study of Myasthenia Gravis, has completed, sponsored by Immunovant Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti-AChR-IgG) in Myasthenia Gravis patients following treatment with RVT-1401 (also known as IMVT-1401) compared to placebo.
Primary Outcome
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. SAEs were defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, or was
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RVT-1401
Study Locations (20)
California
- The Neurology Center of Southern California - Carlsbad
- UC Irvine - MDA ALS and Neuromuscular Center - Orange
- Care Access Research - Pasadena
New York
- Dent Institute - Amherst
- University of Buffalo - Buffalo
- Hospital for Special Surgery - New York
Ontario
- London Health Sciences Centre - London
- Ottawa Hospital Research Institute - Ottawa
- University Health Network Toronto General Hospital - Toronto
Alabama
- IMC/Diagnostic and Medical Clinic - Mobile
Arizona
- Phoenix Neurological Associates - Phoenix
Colorado
- CSNA - Colorado Springs
Connecticut
- Yale School of Medicine Department of Neurology - New Haven
Florida
- Neurological Services of Orlando - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-05-21 |
| Est. Completion | 2020-12-21 |
| Phase | Phase 2 |
What the finished NCT03863080 record still lists
NCT03863080 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 191-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03863080 names 20 study sites across 14 states, led by California, New York, Ontario.
Frequently Asked Questions
What is clinical trial NCT03863080 about?
NCT03863080 is a clinical study titled "A Study of RVT-1401 in Myasthenia Gravis (MG) Patients". The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti-AChR-IgG) in Myasthenia Gravis patients following treatment with RVT-1401 (also known as IMVT-1401) compa...
What is the current status of trial NCT03863080?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2019-05-21. Estimated completion is 2020-12-21.
What conditions does trial NCT03863080 study?
This clinical trial studies the following conditions: Myasthenia Gravis.
What interventions are being tested in trial NCT03863080?
The interventions under investigation include: Placebo (DRUG), RVT-1401 (DRUG).
Who is sponsoring clinical trial NCT03863080?
This trial is sponsored by Immunovant Sciences, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03863080 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03863080's enrollment target sits among peer trials
17 31st of 32 higher than 2 of 32 other Myasthenia Gravis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myasthenia Gravis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
RECRUITING · Phase 2
-
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
RECRUITING · Phase 2
-
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
COMPLETED · Phase 2
-
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI